Raymond James & Associates' 44th Annual Institutional Investors Conference

March 7, 2023

Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT

Disclaimer

Forward-Looking Statements and Market Data

This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the “Company”) about future events based on current views and assumptions. Examples of forward-looking statements made in this presentation include, among others, those related to long-term upside or value, management of risk, anticipated growth and positioning, addressable market estimates, the Company’s mission, vision and strategies, the success of its business model and strategy, anticipated future revenue and guidance, evaluations and judgments regarding the Company’s business, products, technologies, competitive landscape, scalability, plans regarding development and launch of potential future products, and any businesses the Company may seek to acquire or has acquired or has invested in or may seek to invest in, including statements regarding Fulgent Pharma Holdings, Inc. (“Fulgent Pharma”), Inform Diagnostics, CSI Laboratories, Helio Health, Spatial Genomics, and any potential synergies, or transformation of the Company’s business, long-term visions and strategies, included, with respect to Fulgent Pharma, those designated to create a vertically integrated solution for cancer care, the clinical development of Fulgent Pharma’s pipeline and related statements and assumptions regarding development timelines, any potentially accelerated pathway for regulatory approval, the potential safety and efficacy of the nanodrug delivery platform and any related therapeutic candidates, the potential market size for these candidates and platforms and the value of available data, including genomic data and guidance regarding the Company’s future performance and results of operations. The Company’s views and assumptions on which these forward-looking statements are based may prove to be incorrect. As a result, matters discussed in any forward-looking statements are subject to risks, uncertainties and changes in circumstances that may cause actual results to differ materially from those discussed or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those implied by forward-looking statements are disclosed under “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s reports filed with the Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K filed on February 28, 2023, and other reports it files from time to time. Because of these factors, you should not rely upon forward-looking statements as predictions of future events. The forward-looking statements in this presentation are made only as of the date hereof, and, except as required by law, the Company assumes no obligation to update any forward-looking statements in the future. The company’s reports filed with the SEC, including its annual report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 28, 2023 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the company’s website upon their filing with the SEC. These reports contain more information about the company, its business and the risks affecting its business, as well as its results of operations for the periods covered by the financial results included in this presentation.

This presentation also includes market data and forecasts with respect to the industry in which the Company operates. In some cases, the Company relies upon and refers to market data and certain industry forecasts that have been obtained from third-party surveys, market research, consultant surveys, publicly available information and industry publications that the Company believes to be reliable. These data and estimates involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

Non-GAAP Financial Measures

This presentation contains certain supplemental financial measures that are not calculated pursuant to U.S. generally accepted accounting principles (“GAAP”). These non-GAAP measures are in addition to, not a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. A reconciliation of non-GAAP measures to GAAP measures is contained in this presentation.

History of Fulgent



Strategic Vision – A One-Stop Solution for Cancer Care

fulgent VISION

To build a vertically integrated solution to combat cancer

early detection | clinical diagnostics | post treatment monitoring | drug discovery and cancer treatment

fulgent

Leading Genetic Testing Company Offering Tech-Enabled Diagnostic Solutions

Nano-Drug Delivery Platform

FULGENT PHARMA

Exciting Cancer Therapeutic Opportunity Realizing Precision Medicine Potential

Therapeutic and Diagnostic Entity Providing Comprehensive Solutions Across the Cancer Care Continuum

- Vertically integrated “one-stop” solution across the healthcare chain following the CSI, Inform Diagnostics, and Pharma acquisitions
- Proprietary nano drug delivery technology platform serves as an underpinning technology between diagnostic and pharm to help create a more sustainable and profitable business model in precision medicine for years to come
- Addition of a talented scientific team creates a strong synergy and competitive advantage that may be leveraged across the combined business
- Potential near-term opportunity includes shortened 505(b)(2) drug development and commercialization timelines and potential long-term opportunity leverages large data insights and novel analytical tools from diagnostics business to enable additional precision medicine pipeline through organic or partnered development strategies
- Commitment to continue growing diagnostic and therapeutic opportunities through organic investments and M&A
- Seasoned management team along with strong cash position allow Fulgent to enter therapeutic opportunities while managing risk

Long-Term Vision: Fulgent Continuum of Care

Diagnosis

Therapy

Database + Drug Discovery + Patient Care

fulgent

- Transforms from a service company to a combined diagnostic and therapeutic company focused on precision medicine
- Large oncology market opportunity
- Careful pipeline management will responsibly engage therapeutic opportunities while managing potential risks
- Valuable, diverse assets and future sustainable revenue and margins

FULGENT PHARMA

- Well-funded by diagnostics to advance H&N therapy trials and commercialization process
- Genomics data accelerates pipeline therapeutics development, e.g. spatial biology for tumor micro-environment profiling
- Long-term opportunity to leverage data insights from diagnostics to enable precision medicine through proprietary or partnered development strategies
- Manufacturing capability to aid drug development

DIAGNOSTICS

Building Diagnostics Platform and Capabilities



What Sets Fulgent Diagnostics Apart?



1) Represents genes covered by single-gene tests.

Proprietary Technology Platform

Differentiated Technology...

- Engineered genetic biochemistry, including reagents and probes
- Data suppression and comparison algorithms
- Adaptive learning software
- Automated reporting

...Provides a Multitude of Advantages

- Broad test menu
- Ability to rapidly develop and launch new tests
- Customizable test offerings
- Lower costs per billable test
- High efficiency



Our Menu is Scalable and Affordable to Customers



Oncology Testing Platforms

FISH

- Expansive heme and solid tumor menu
- STAT testing available - PML/RARA <1 day TAT
- CD138 cell enrichment for PCM
- 3-5 Day turnaround time

Histology

- 225+ stains
- Platform agnostic
  - Roche, Agilent and Leica IHC
- Three levels of service – Tech, Global, Consultative
- PD-L1 - Various IVD platforms and indications
- <1-2 Day turnaround time

Cytogenetics

- Oncology and constitutional
- >20% abnormality detection rate
- Mitogen stimulation/dual culture
- DSP30 (detection of B-cell disorders)
- Interleukin 4 for plasma cell myeloma
- Phytohemagglutinin and Interleukin 2 (detection of T-cell disorders)
- Children's Oncology Group approved
- 5-7 Day turnaround time

Flow Cytometry

- 10-color platform
- Comprehensive panel design
- High-sensitivity for paroxysmal nocturnal hemoglobinuria
- Expert analysis and interpretation
- 12-24 Hour turnaround time

Molecular

- Hematology and solid tumor menu
- Extensive single gene menu
- NGS
- 5-7 Day turnaround time [NGS 10-14 Days]

NGS Testing – Panel Deep Dive

Comprehensive Beacon Carrier Screening Tests

Beacon ACOG / ACMG Guidelines Panel

The ACOG/ACMG panel screens for common genetic disorders seen in the general population

Gene Count: 6

Beacon Ashkenazi Jewish Panel

The Ashkenazi Jewish carrier screens for pathogenic carrier variants known to cause recessive genetic disorders

Gene Count: 61

Beacon Focus Panel

The Focus Carrier screen is a pan-ethnic screen that looks for pathogenic mutations known to cause autosomal recessive and X-linked disorders

Gene Count: 30

Beacon Expanded Panel

The Expanded Panel screens for more than 400 recessive and X-linked conditions that covers people of all ethnic backgrounds

Gene Count: 427

Beacon787 Panel

One of the largest panels available for those seeking the most comprehensive testing option

Gene Count: 787

fulgent

Beacon Carrier Screening

- NGS of entire genes, not just hotspots
- Deletion and duplication analysis
- Proprietary algorithms for pseudogenes
- TAT: 2 weeks

PHARMA

$68M

Q4 Revenue

+97%

Q4 YoY Core Revenue Increase

18,400+ GENES | 900+ PANELS
CUSTOMIZABLE OFFERINGS

Positioned for Growth

1 Proprietary technology platform allows for rapid scaling of a **broad, flexible test menu**

2 **Next-generation sequencing (NGS)** platform complemented with growing portfolio of **emerging testing technologies** with a focus on oncology

3 Well-positioned to execute on a growth strategy that includes **organic and inorganic initiatives,** including:

- Transformational acquisition of **Inform Diagnostics**
- Ramping of **CSI Labs**
- Scaling partnerships – **Helio Genomics and Spatial Genomics**
- Potential **future acquisitions** with a strategy of short- and long-term ROI, tangible synergies, and efficient capital deployment

Nano-Drug Delivery Platform Overview



Platform Advantage:
Soluble in both water and various organic solvents and capable of hot melt mixing with APIs

- Many drug candidates in the industry failed during preclinical and clinical development and testing due to poor water solubility
- Nanoencapsulation produces amorphous drug candidates with improved solubility and potentially enhanced absorption, drug PK profiles, safety and efficacy
- Broadly applicable to both IV and oral drug delivery formulations
- Potentially shortened development timeline
- Plug and play drug delivery platform provides multiple shots on goal
- Simple and low-cost production process

FID-007 Program Overview

FID-007 Phase I First in Human Clinical Trial – Preliminary Findings

- Dose levels up to 125 mg/m^2/week with manageable safety profile, without yet reaching MTD
  - Dosing at 160 mg/m^2/week is ongoing
- There is preliminary evidence of anti-tumor activity in heavily pre-treated patients across different tumor types
- Partial clinical data presented at ASCO 2021

FID-007 Phase I Preliminary Highlights (as of 6/10/22):

H&N Cancer

- 100% Disease Control Rate (DCR[1]) and 33% Overall Response Rate (ORR) were observed in 6 heavily treated H&N patients

Ampullary/Pancreatic

- 75% DCR and 50% ORR were seen in 4 heavily treated ampullary and pancreatic patients

Immune Checkpoint Inhibitors (ICIs) Resistant Patients

- 67% DCR and 33% ORR were seen in 6 heavily treated patients of different types of cancer with PD-1 or PD-L1 antibody treatment as the last line prior to enrollment in FID-007 trial

Anticipate more data to be published in 2023

Note: all findings are preliminary

1. DCR includes Stable Disease (SD), Partial Response (PR), Complete Response (CR)

Potential Market Opportunity for FID-007



Note: U.S. opportunity shown
Sources: Evaluate Pharma, Wall Street research, and management pricing expectations
1. H&N market opportunity for both 2nd line and 3rd line therapy
2. Ampullary market opportunity for 2nd line therapy

FID-007 Clinical and Regulatory Plan

- Wholly-owned drug candidate initially focused on Head & Neck (H&N), Pancreatic/Ampullary cancers
  - Seeking initial therapeutic indication for 2nd or 3rd line treatment of H&N cancer
  - Exploring potential ampullary or ICI resistant
- Potential FDA approval strategy uses 505(b)(2) studies, which may shorten clinical trial process and accelerate timeline to commercialization



Additional candidates in preclinical development focused on various cancers

FINANCIALS

Summary Financial Performance

$55M Core Revenue[1] in Q4'22

97% growth year-over-year

$254M LTM Operating Cash Flow as of Q4'22



(1) Core Revenue excludes NGS COVID-19 test volume

Financial Performance: Revenue Profile

Total Revenue

($ in thousands)



Total Core Revenue[1]

($ in thousands)



(1) Core Revenue excludes NGS COVID-19 test volume

2023 Financial Guidance

	Q1 2023	Full Year 2023
Total Revenue	$56 M -83%y/y *Core + 123% y/y*[1]	$240 M *-61%y/y* *Core + 32% y/y*[1]
GAAP EPS	--	($2.50)
Non-GAAP EPS	--	($1.25)

2023 Revenue does not include any expected COVID-19 testing revenue

Core growth reflects momentum across the business, including precision diagnostics, anatomic pathology, and pharma services

(1) Core Revenue excludes NGS COVID-19 test revenue for more accurate year over year comparison purposes.

Balance Sheet

(in 000's)	December 31, 2021	December 31, 2022	
Assets			
Cash & cash equivalents	$ 164,894	$ 79,506	(1)
Marketable securities	285,605	446,729	(1)
Trade accounts receivable, net	138,912	52,749	
Other current assets	22,549	48,889	
Total current assets	611,960	627,873	
Marketable securities, long-term	485,047	326,648	(1)
Redeemable preferred stock investment	21,965	12,385	
Fixed assets, net	62,287	81,353	
Intangible assets, net	35,914	150,643	
Goodwill	50,897	143,027	
Other long-term assets	10,650	44,124	
Total assets	**$ 1,278,720**	**$ 1,386,053**	
Liabilities and Stockholders' Equity			
Accounts payable	$ 20,494	$ 23,093	
Income tax payable	787	—	
Contract liabilities	14,570	3,199	
Customer deposit	19,806	10,895	
Investment margin loan	15,137	14,999	
Other liabilities	42,046	63,992	
Total liabilities	112,840	116,178	
Stockholders' equity	501,911	486,588	
Accumulated income	656,838	780,097	
Total Fulgent stockholders' equity	1,158,749	1,266,685	
Noncontrolling interest	7,131	3,190	
Total stockholders' equity	1,165,880	1,269,875	
Total liabilities and stockholders' equity	**$ 1,278,720**	**$ 1,386,053**	

(1) $853M in cash and investments.

Non-GAAP Financial Adjustments

(in 000's)	2021				FY	2022				FY
	Q1	Q2	Q3	Q4	2021	Q1	Q2	Q3	Q4	2022
Revenue	$359,429	$153,616	$227,868	$251,671	$992,584	$320,268	$125,341	$105,655	$67,704	$618,968
Cost of revenue	74,075	35,858	43,466	62,134	215,533	77,725	60,065	59,560	54,717	252,067
Gross profit	$285,354	$117,758	$184,402	$189,537	$777,051	$242,543	$65,276	$46,095	$12,987	$366,901
Gross margin	79.4%	76.7%	80.9%	75.3%	78.3%	75.7%	52.1%	43.6%	19.2%	59.3%
Equity-based compensation included in cost of revenue	674	692	962	1,235	3,563	1,465	2,243	2,475	2,521	8,704
Non-GAAP gross profit (excluding equity-based compensation)	$286,028	$118,450	$185,364	$190,772	$780,614	$244,008	$67,519	$48,570	$15,508	$375,605
Non-GAAP gross margin	79.6%	77.1%	81.3%	75.8%	78.6%	76.2%	53.9%	46.0%	22.9%	60.7%
Operating expenses										
R&D	$5,422	$5,312	$6,021	$7,464	$24,219	$5,989	$6,905	$7,507	$8,509	$28,910
S&M	5,008	5,219	6,012	8,200	24,439	7,940	10,866	9,859	10,253	38,918
G&A	8,002	8,329	12,299	22,102	50,732	25,775	30,240	26,266	28,793	111,074
Amortization of intangible assets	0	0	797	911	1,708	906	1,575	2,006	2,010	6,497
Restructuring costs	0	0	0	0	0	0	2,896	105	(26)	2,975
Total operating expenses	18,432	18,860	25,129	38,677	101,098	40,610	52,482	45,743	49,539	188,374
Operating profit (loss)	$266,922	$98,898	$159,273	$150,860	$675,953	$201,933	$12,794	$352	($36,552)	$178,527
Operating margin	74.3%	64.4%	69.9%	59.9%	68.1%	63.1%	10.2%	0.3%	-54.0%	28.8%
Equity-based compensation included in operating expenses	2,288	2,834	3,412	3,785	12,319	4,151	5,787	6,497	7,501	23,936
Acquisition-related cost included in G&A	0	0	0	0	0	1,251	5,158	166	1,359	7,934
Non-GAAP operating profit (loss) (excluding equity-based compensation, amortization, restructuring costs & acquisition-related costs)	$269,884	$102,424	$164,444	$156,791	$693,543	$209,706	$30,453	$11,601	($23,187)	$228,573
Non-GAAP operating margin	75.1%	66.7%	72.2%	62.3%	69.9%	65.5%	24.3%	11.0%	-34.2%	36.9%

THANK YOU